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Abstract 
Cardiac fibrosis stems from the changes in the expression of fibrotic genes in cardiac fibroblasts 
(CFs) in response to the tissue damage induced by various cardiovascular diseases (CVDs) leading 
to their transformation into active myofibroblasts, which produce high amounts of extracellular 
matrix (ECM) proteins leading, in turn, to excessive deposition of ECM in cardiac tissue. The 
excessive accumulation of ECM elements causes heart stiffness, tissue scarring, electrical 
conduction disruption and finally cardiac dysfunction and heart failure. Curcumin (Cur; also 
known as diferuloylmethane) is a polyphenol compound extracted from rhizomes of Curcuma 
longa with an influence on an extensive spectrum of biological phenomena including cell 
proliferation, differentiation, inflammation, pathogenesis, chemoprevention, apoptosis, 
angiogenesis and cardiac pathological changes. Cumulative evidence has suggested a beneficial 
role for Cur in improving disrupted cardiac function developed by cardiac fibrosis by establishing 
a balance between degradation and synthesis of ECM components. There are various molecular 
mechanisms contributing to the development of cardiac fibrosis. We presented a review of Cur 
effects on cardiac fibrosis and the discovered underlying mechanisms by them Cur interacts to 
establish its cardio-protective effects.  
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Cardiac fibrosis is an outcome of a diverse range of conditions including diabetes and 
cardiovascular diseases (CVDs) resulting in fibrosis of heart and thereby heart failure.  In these 
conditions, fibrosis is primarily aimed to correct the maladaptive developed injury [1,2]. Cardiac 
fibrosis stems from the expression of fibrotic genes leading to macrophage-mediated trans-
differentiation of cardiac fibroblasts (CFs) into active myofibroblasts responsible for secreting 
proteins involved in contraction such as α-smooth muscle actin (α-SMA) and extracellular matrix 
(ECM) proteins like collagen and elastin [3-5]. In cardiac tissue, ECM is responsible for supporting 
the cardiac cells’ alignment within the tissue to have efficient coupling with other cells nearby 
throughout the contraction. Normally, the synthesis and degradation procedures relating to ECM 
components are highly regulated to keep a balance. In case of conditions such as destruction caused 
by myocardial infarction (MI), the balance between ECM synthesis and degradation is disrupted 
to compensate for the damage resulting in excessive ECM accumulation [6,7]. The excessive 
deposition of ECM in cardiac tissue (cardiac fibrosis) is detrimental by itself causing heart 
stiffness, electrical conduction disruption, development of tissue scars containing high amounts of 
collagen, left ventricular hypertrophy and ultimately cardiac dysfunction and heart failure [3]. 
Although different treatments including angiotensin converting enzyme (ACE) inhibitors and 
angiotensin II receptor blockers have been proposed for the treatment of cardiac fibrosis none of 
them has been proven effective, especially in heart failure where the incidence of fibrosis is high 
[8]. Hence, there is an unmet need to find novel strategies against the development and progression 
of cardiac damage mediated by fibrosis resulting from CVDs. 
Curcumin (Cur), also known as diferuloylmethane, is a polyphenolic compound derived from 
Curcuma longa plant rhizome and the main curcuminoid in the Indian spice, turmeric. This 
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phytochemical has been revealed to exhibit different functions in living systems comprising anti-
thrombotic, anti-inflammatory, anti-oxidant, anti-proliferative, anti-angiogenic and pro-apoptotic, 
making it or some of its active substances potential therapeutic agents for selected CVDs [9,10].  
The remedial use of this compound goes back to traditional medicine in China and India [11]. 
Cumulative evidence has suggested curcumin to play a positive role in protection against cardiac 
fibrosis through modulating different molecular pathways via acting on a variety of cytokines, 
growth factors, and their relating receptors, transcription factors especially those involved in the 
regulation of cell proliferation, and enzymes [12,13,11].  
Molecular mechanisms underlying cardiac fibrosis development 
A fibrotic response is the consequence of a change in expression of genes encoding molecules 
activating various signaling pathways, including growth factors, cytokines and chemokines that 
are triggered by internal or external stressors. Some of the most important molecules involved in 
the process of CF differentiation into myofibroblast and their migration include transforming 
growth factor β (TGF-β), angiotensin II (AngII), platelet-derived growth factor (PDGF)-D, 
connective tissue growth factor (CTGF), endothelin-1 and interleukin-18 (IL-18) [14-16]. Figure 
1 highlights some of the fibrosis mediators and their role in differentiating fibroblasts into 
myofibroblasts.  
Over-expression of AngII activates the Ang II type 1 (AT1) receptor giving rise to cardiac fibrosis 
by inducing CF proliferation and migration, elevated level of myocardial apoptosis and excessive 
accumulation of collagen type I (Col I), collagen type III (Col III) and fibronectin (FN) ECM 
elements [17-20]. In the presence of Ang II, plasminogen activator inhibitor (PAI)-1 is over-
expressed in cardiac fibroblasts and the myocardium resulting in an increment in ECM synthesis 
by fibroblasts, decrement in ECM degradation and metalloproteinase inhibition [21,22]. 
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Transforming growth factor β1 (TGF-β1) is another molecule involved in triggering fibrosis and 
hypertrophy [23][24]. This fibrotic activity of TGF-β1 seems to be modulated by acetyltransferase 
(HAT) activity of transcriptional co-regulator of p300 via the mediation of Smad, leading to 
enhanced collagen production and fibrotic response initiation [25]. 
Several in vivo studies demonstrated that the expression of connective tissue growth factor (CTGF) 
expression is increased in arteries and left ventricle of patients with atherosclerosis and 
hypertension suggesting both the vascular and cardiac fibrosis are amplified as a consequence of 
CF and induction of vascular smooth muscle cell proliferation [26,27]. 
Peroxisome proliferator-activated receptor-γ (PPAR-γ or NR1C3) is another molecule involved in 
the development of cardiac fibrosis [28]. Once PPAR-γ turns into its activated form as a result of 
binding to its relevant ligand, it is able to form a heterodimer with retinoid X receptor (RXR) and 
bind the DNA through PPAR-responsive regulatory elements to regulate the expression of a 
variety of genes involved in a wide range of biological activities [29]. More specifically, PPAR-γ 
regulates fibrotic and hypertrophic processes in cardiovascular apparatus in response to stress 
signals [30]. 
The family of serine/threonine protein kinases C (PKC) encompasses different isozymes.  Their 
activity is associated with pathogenic cardiac issues, including cardiac fibrosis [31]. The activation 
of a PKC is triggered in response to an extracellular signal activating phospholipase C (PLC) 
leading to the formation of diacylglycerol (DAG) and inositoltriphosphate (IP3) elevating the 
intracellular ca2+ content. The PKC is then activated in response to high ca2+ level in the cytosol 
by binding to DAG located in membrane inducing several downstream signaling pathways such 
as mitogen-activated protein kinase (MAPK) pathway contributing in a range of different 
intracellular effects involving modulating cell growth and proliferation [32,33]. Various in vitro 
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and in vivo investigations suggest that in certain conditions such as high amounts of glucose 
(hyperglycemia) or free fatty acid (FFA) in the bloodstream, the production of DAG increase with 
associated pathological changes in the cardiac muscles [31,34]. The regulatory effects of PKCs on 
matrix metalloproteinase (MMP) quantity and function have also been proven to be evident as they 
enhance the activity of MMP-2 and MMP-9 via MAPK and MMP-9 through JNK signal 
transduction pathways [34].  
In case of exposure to a stress signal like hypertension-induced pressure overload, it has been 
shown that fibrogenic gene expression is stimulated by the activity of sequence-specific DNA 
binding transcription factors comprising SMAD2/3, serum response factor (SRF), myocardin-
related transcription factors (MRTFs) and nuclear factor of activated T cells (NFAT) [35]. 
Mechanisms of curcumin effect on cardiac fibrosis 
Curcumin (Cur), is a natural polyphenol found in turmeric and is derived from Curcuma longa.  
The potential pharmacological and therapeutic effects of Cur have been studied extensively in a 
wide range of conditions [36-38]. It has pleiotropic effects in a variety of cells including cardiac 
cells. Given its hydrophobic nature, presence of a β-diketone moiety and active methylene group 
Cur is metabolized in the liver via aldo-keto reductase and has poor bioavailability [39,40]. To 
circumvent these various modified forms of native curcumin [41-44] as well as its synthetic 
analogs [45] and derivatives [46] have been used in various studies. The Cur derivatives  and 
analogues which have potential anti-fibrotic effects on heart are (2E,6E)-2,6-bis(2-
(trifluoromethyl)benzylidene) cyclohexanone, also known as C66 [47], J17 [(2E,5E)-2-(3-
Hydroxy-4-methoxybenzylidene)-5- (2 nitrobenzylidene) cyclopentanone][48] and 
tetrahydrocurcumin (THC) [49]. In the following section, we have reviewed various effects of Cur 
and its metabolites on cardiac fibrosis and potential molecular mechanisms. 
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Inhibition of MMPs expression 
It has been shown that Cur restored the reduced expression of MMP-2 and MMP-9 after HF 
induction in New Zealand rabbits. Also, the high level of collagen accumulation was reduced in 
Cur-subjected animals suggesting an anti-fibrotic activity for this compound [50]. 
TGF-β suppression 
Cur reversed changes resulted from TGF-β treatment by suppressing the augmented expression of 
PAI-1 protein in human liver-derived HepG2 cells [51]. In this study, Cur was able to exert almost 
the same effects as simvastatin, a lipid-lowering medication [51]. In neonatal SD rat CFs reported 
that Cur administration blocks the pro-fibrotic activity of TGF-β1 through reduction of α-SMA 
and Col I at both mRNA and protein levels and suppression of Smad2 and p38 MAPK activation 
levels [52].  
A recent investigation on TGF‑β1 stimulated human CFs pre-treated with Cur [12] showed a 
dramatic reduction of α‑smooth muscle actin (α‑SMA), collagen type Iα (COLA)-1 and COLA3 
expression. Cur was also able to suppress CF proliferation following TGF‑β1 treatment and 
stimulate G2/M phase cell cycle arrest. Cur exposure inhibited Smad2/3, p38 MAPK and ERK 
phosphorylation and consequently down-regulated the expression of cell cycle protein. 
Conversely, CFs incubated only with Cur did not exhibit any of these changes and the outcomes 
were consistent with the anti-proliferative and anti-collagen accumulation activities of Cur 
activities through TGF‑β1 pathway [12].  
Cur dramatically reduced the excessive accumulation of collagen, the expression of TGF-β and 
CTGF pro-fibrotic genes as well as the protein levels of collagen I and matrix metalloproteinase-
9 (MMP-9) in Cur-treated C57BL/6 mice fed on a high-fat diet (HFD) [53]. This suggests that  Cur 
neutralizes the adverse effects of HFD on the cardiac tissue [53]. Furthermore, curcumin pre-
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exposure of H9c2 embryonic rat heart-derived cells followed by treatment with palmitate (PA) 
resulted in a reversal of hypertrophy induced by PA [53]. The PA-stimulated high expression level 
of TGF-β was shown to be down-regulated in cells pre-treated with Cur [53]. 
Altering MAPK phosphorylation 
Soetikno, and colleagues [54] assessed the cardio-protective effect of curcumin in high glucose 
(HG)-related cardiomyopathy in SD rats by streptozotocin (STZ) injection. As a result of the 
induction of diabetes, the PKC-α and -β2 isozymes were translocated to the membrane as an 
indication of their activation, which was inhibited following Cur treatment. The increased amount 
of phosphorylated p38MAPK and ERK1/2 in diabetic animals-related tissue samples from left 
ventricle was reduced by following treatment with Cur [54]. The expression of TGF-β, osteopontin 
and p300 transcriptional coactivator as an indicative of anti-fibrotic Cur activity was decreased 
which was shown by reduced  ECM deposition and shrinkage of fibrotic areas [54]. 
In another study diabetes was induced in SD rats by feeding them on a high energy diet and a low-
dose streptozotocin (STZ) injection [55]. Heart specimens from Cur-treated diabetic rats exhibited 
lower collagen type I and III accumulation compared to Cur-untreated animals. Additionally, TGF-
β1, TβR II and phosphorylated Smad 2/3 were detected only at remarkably low levels. However, 
the expression of Smad 7 was enhanced in those rats [55]. When human CFs were subjected to 
Cur, accompanied by high glucose (HG) or treatment with TGF-β1. The over-activity of 
AMPK/p38 MAPK stimulated by HG or TGF-β1 was found to be suppressed and the collagen 
synthesis was attenuated in those cells as a result of Cur treatment [55]. 
Suppression of Smads phosphorylation 
Bugyei-Twum et al. pre-treated H9c2 rat cardiomyoblast cells using 25 μM Cur followed by HG 
administration. The Cur pre-treatment led to inhibition of the HG-stimulated p300 activity. When 
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neonatal rat fibroblasts were treated with Cur there was a significant reduction in collagen 
synthesis confirming its counter-HG/ TGF-β behavior [56]. Cur also reduced the level of 
acetylated Smad2 in TGF-β-stimulated H9c2 cardiomyoblasts. The up-regulated Smad7 mRNA, 
induced by treatments with HG or TGF-β, was suppressed by Cur both in vitro and in vivo. The 
Cur-treated diabetic Ren-2 rats showed a reduced amount of hypertrophy in heart, ECM synthesis 
and restoration of diastolic function [56]. 
The cardiac fibroblasts isolated from Sprague-Dawley (SD) rats were treated with Cur along with 
TGF-β1 or Ang II [57]. It was found that Cur enhanced the activity of matrix metalloproteinase 
(MMP)-2 and diminished the levels of the phosphorylated extracellular signal-regulated kinase 
(ERK) 1/2 in the presence of Ang II. Analyzing CFs co-treated with Cur and TGF-β1 showed 
reduced expression levels of phosphorylated Smad2/3 and Akt [57]. This study demonstrated that 
Cur administration attenuates CF proliferation and migration and keeps their collagen production 
at baseline level regardless of the presence of TGF-β1 or Ang II [57]. 
Inhibition of toll-like receptor 2 expression 
To gain insight into the cardioprotective effects of Cur after ischemia/reperfusion (I/R) injuries, 
SD rats were first orally administered with 300 mg/kg/day Cur for seven days before undergoing 
I/R injury [58]. The expression of toll-like receptor 2 (TLR2), known to contribute in myocardial 
infarction, was prominently amplified in the infarct zone of IR rat models; however, the expression 
of TLR4 showed a constant pattern [58]. The up-regulation of TLR2 was reversed in Cur-treated 
animals. There was a reduction of macrophage infiltration (CD68) and high mobility group box 1 
in Cur-treated IR rat models, whereas, their levels increased in the absence of Cur post the IR 
injury [58]. Furthermore, comparing changes in neonatal rat-derived myocardial cells stimulated 
by tumor necrosis factor (TNF)-α, peptidoglycan (PGN) or hypoxia/reoxygenation (H/R) in the 
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presence and absence of 10 μM Cur, the inhibitory effect of Cur on over-expressed TLR2 and 
monocyte chemoattractant protein (MCP)-1 became apparent [58].  
Increasing Akt phosphorylation 
Experimental diabetes was induced in Wistar rats via a high-fat diet (HFD) and intraperitoneal 
(I.P.) injection of STZ [59] followed by administration of Cur. The ratio of fibrosis area to the 
entire myocardial area in diabetic rats was attenuated by curcumin  [59]. Cur declined diabetic 
cardiomyopathy by promoting protein kinase B (Akt) and GSK-3β phosphorylation [59]. 
 
PPAR-γ activation 
In spontaneously hypertensive rats (SHRs) Cur treatment reduced the Ang II levels in the blood, 
the ratios of heart weight/body weight and left ventricle weight/body weight, systolic blood 
pressure and the expression levels of CTGF, PAI-1, Col III, and FN [13]. There was also 
upregulation of A PPAR-γ after Cur treatment.  Left ventricle samples showed a reduction of 
collagen accumulation after daily oral treatment of Cur. In groups concomitantly treated with Cur 
and GW9f662 (PPAR-γ antagonist), the anti-fibrotic activity of curcumin was overturned (Figure 
2) [13]. Pretreatment of cardiac fibroblasts with Cur suppressed the Ang II-promoted expression 
of CTGF, PAI-1, collagen III (Col III/COLA-3), FN, TGF-β1 and also inhibited phosphorylation 
of Smad2/3. It also increased the PPAR-γ expression and binding capability in a dose-dependent 
manner. GW9662 pre-treatment, on the other hand, exerted negative effects on Cur-induced anti-
fibrotic activities [13] suggesting that Cur can suppress the cardiac fibrosis in SHRs via modulating 
PPAR-γ and TGF-β1/Smad2/3 signaling interaction [13]. 
This is a post-peer-review, pre-copyedit version of an article published in Heart Failure Reviews. The 
final authenticated version is available online at: https://doi.org/10.1007/s10741-019-09854-6. 
10 
 
When SD rats after left coronary artery ligation were exposed to Cur [60] there was notable 
shrinkage of the fibrosis area due to myocardial infarction (MI) after oral treatment of Cur in a 
dose-dependent manner [60].  
Affecting angiotensin receptors expression 
Ang II-perfused Sprague Dawley (SD) rats were used to investigate the anti-fibrotic effect of 
dietary Cur post-Ang II infusion [61]. Cur was found reduce the fibrosis in the intra-cardiac vessels 
and myocardium by dramatic suppression of AT1 receptor expression after four weeks and, 
inversely, up-regulation of AT2 receptor expression enhancing through time suggesting dual 
effects of Cur on AT1 and AT2 receptors [61]. The elevated numbers of macrophages and alpha-
SMA-expressing myofibroblasts accumulated in specimens from Ang II-injected rats was 
significantly decreased following administration of dietary Cur over 28 days [61]. Cur treatment 
also down-regulated the expression of TGF-β1 and phosphorylated-Smad2/3, suppressed the 
synthesis of collagen I and reduced the collagen-rich areas [61]. Finally, the reduced ACE2 levels 
after Ang II injection was abrogated by Cur intake [61]. 
Reducing inflammation 
An in vivo study after intraperitoneal (I.P.) injection of Cur on hind limb ischemia mouse model 
revealed amelioration of cardiac fibrosis damages occurred by ischemia [62]. This study 
demonstrated that Cur-induced cardio-protective outcomes are mediated by inhibition of NF-kB 
activation and macrophage infiltration and down-regulation of inflammatory markers (TNF-α, IL-
1 and IL-6) [62,38]. 
Restoring sirtuin protein 1 inhibition 
Xiao et al. [8], studied the Cur-induced changes in C57BL/6J wild-type male mice about one 
month after MI induction. Four weeks post-MI induction, the experiments revealed that there was 
This is a post-peer-review, pre-copyedit version of an article published in Heart Failure Reviews. The 
final authenticated version is available online at: https://doi.org/10.1007/s10741-019-09854-6. 
11 
 
significant shrinkage of interstitial areas affected by fibrosis in Cur-received animals. The 
expression levels of collagen I, collagen III and TGF-β1 were found to be down-regulated. The 
Cur treatment led to the restoration of post-MI inhibition of sirtuin protein 1 (SIRT1), a histone 
deacetylase. Cur suppressed the proliferation and migration of Ang II-exposed CFs, decreased the 
deposition of collagen and down-regulated the expression of matrix metalloproteinase (MMP)-9 
and -2 [8]. Furthermore, the siRNA-SIRT1-mediated down-regulation of SIRT1 in Ang II-
incubated CFs suggested the involvement of SIRT1 in anti-fibrotic property of Cur [8]. 
Inhibiting expression of autophagy markers 
Another recent study investigated the contribution of autophagy in anti-fibrotic and anti-
hypertrophic activities of  Cur in ISO-induced rat models of cardiac hypertrophy and fibrosis [63]. 
The heart weight/body weight ratio in Cur-treated hypertrophic rat models decreased by 13.1% 
and reversed the ISO-induced expression changes in hypertrophic markers including atrial 
natriuretic peptide (ANP), α-myosin heavy chain (α-MHC or MYH6), β-MHC (MYH7) and 
MYH7B [63]. The extent of interstitial fibrosis area formed following ISO exposure was limited 
by Cur intervention. The expression of genes encoding fibrotic markers of procollagen I and 
procollagen III, which were increased by ISO, decreased to roughly more than 50% as a result of 
treatment with Cur. Although ISO suppressed mTOR expression, treatment with Cur restored 
mTOR expression. The expression of autophagy markers, including LC3 and Belin-1, was up-
regulated the presence of ISO, while Cur treatment completely abolished this effect [63].  
Cur pharmacokinetics and safety 
Cur is known to have poor bioavailability limiting its application as a therapeutic agent. Its 
relatively low absorption, rapid metabolism and clearance from the body contribute to its poor 
bioavailability [64]. The high lipophilic property of Cur contributes to its low solubility in aqueous 
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environments [65]. Cur is poorly absorbed when orally administered (almost undetectable in 
plasma, liver and brain after 30 min), while it is detectable (at low levels) in animals with parenteral 
administration [66]. Cur is both chemically and metabolically unstable [67]. Once administered in 
neutral to alkaline environments, Cur rapidly (within 30 min) degrades to form mainly 
bicyclopentadione and autoxidation products, and to a less extent ferulic acid, feruloyl methane 
and vanillin [68]. In acidic environments, on the other hand, the degradation rate is significantly 
lower [64]. 
After oral ingestion, only a low proportion of Cur is absorbed through the intestinal tract which 
undergoes rapid metabolism in plasma and liver and the rest are excreted in feces [64]. While being 
metabolized, the absorbed Cur go through two different phases including reduction and 
conjugation. In the reduction phase, the double bonds are reduced via NADPH-dependent 
curcumin/dihydrocurcumin reductase. In the next phase, the previously reduced metabolites of Cur 
and Cur itself undergo β-glucuronidase/sulfatase enzymes- mediated conjugation with glucuronic 
acid or sulfuric acid-producing glucuronides and sulfates in the liver. A proportion of these water-
soluble products are then excreted into the duodenum via bile, and the rest is released into the 
blood and excreted through the urine [64,65]. Only the free form of Cur is active while the 
conjugated forms of Cur are inactive and are rapidly eliminated from the body [65,68]. Cur is well 
tolerated and causes no harm even when administered at very high doses [67]. 
Curcumin analogues and cardiac fibrosis 
In view of the poor bioavailability of Cur after oral administration [69], several studies have been 
conducted on the evaluation of anti-fibrotic properties of Cur derivatives to address this limitation.  
Pang and colleagues [47] used (2E,6E)-2,6-bis(2-(trifluoromethyl)benzylidene) cyclohexanone, 
also known as C66, a synthetic curcumin derivative, in type 1 diabetic mice to validate its 
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cardioprotective potential. The elevated heart weight/body weight ratio was decreased after a two-
month treatment suggesting a beneficial role of C66 in preventing pathological changes in cardiac 
tissue and potentially reversing diabetic cardiomyopathy [47]. The C66 compound was also used 
in another study performed on streptozotocin-injected C57BL/6 mice to evaluate its protective 
effects against diabetic cardiomyopathy [70]. The three-month administration of C66 at a 
concentration to diabetic mice reduced cardiac fibrosis and cardiac function decrement compared 
to C66-untreated diabetic mice. The cardioprotective function of C66 was suggested to be due to 
down-regulation of c-Jun NH2-terminal kinase (JNK) activation [70]. 
To shed more light on molecular mechanisms behind the cardio-protective action of C66 when 
diabetic JNK2−/− and wild‑type (WT) mouse models were fed with C66 [71] there was a reduction 
in diabetes-induced cardiac fibrosis due to its inhibitory effect on the JNK2 activity. In contrast to 
non-treated WT diabetic mice, there was a reduction in expression of TGF‑β1, CTGF, and PAI‑1 
pro-fibrotic factor in C66-treated WT diabetic mice resulting in reduced collagen deposition in the 
interstitial areas. On the other hand, there were no fibrotic changes in cardiac tissues from JNK2−/− 
mouse models [71]. 
Since chronic kidney diseases (CKD) are accompanied by CVD-related complications like cardiac 
fibrosis, a compound called theracurmin with the similar formulation as Cur was fed to CKD SD 
rat models by gavage [72]. After treatment with theracurmin, both cardiac structure and function 
improved and cardiac fibrosis and hypertrophy were reduced in rats with CKD. The assessment of 
expression of pro-fibrotic and pro-hypertrophic genes in heart tissues isolated from the treated rats 
showed the suppressive effects of theracurmin on TGF-β1, β-MHC, and type I collagen. Besides, 
theracurmin lowered the phosphorylation level of Smad2 [72]. 
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A Cur analog called J17 [(2E,5E)-2-(3-Hydroxy-4-methoxybenzylidene)-5- (2 nitrobenzylidene) 
cyclopentanone] [48] was tested as a possible Cur alternative to reverse cardiomyopathy and 
fibrosis established by diabetes. There was a reduction of fibrosis via AKT signal transduction 
silencing in H9C2 rat myoblast cells cultured in the presence of DMSO-dissolved Cur and J17. 
These were added thirty minutes before high glucose-mediated fibrosis stimulation.  There was a 
stronger dose-dependent inhibitory activity with J17 compared to the Cur-induced inhibitory 
effects [48]. Male C57BL/6 mice were subjected to either J17 solubilized in 0.5% sodium carboxyl 
methyl cellulose (CMC-Na) at a concentration of 10 mg/kg or Cur at a concentration of 50 mg/kg 
administered by gavage eight days after the induction of diabetes mellitus [48]. The heart tissue 
sections from which received Cur- and J17 showed a significant attenuation of collagen deposition 
and cardiac fibrosis. The over-expression of collagen type I and TGF-β were attenuated in diabetic 
mice treated with J17 to physiological level [48]. Similarly, the level of TNF-α and ICAM-1 
transcripts in heart specimens were reduced to their relevant normal physiological levels following 
the administration of J17 [48]. This suggests a protective effect of J17 against fibrosis and other 
cardiac pathological changes after initiation of a fibrosis response due to diabetic hyperglycemia 
[48]. 
When a metabolite of Cur, tetrahydrocurcumin (THC), was orally administered to STZ-induced 
diabetic mice [49], there was improvement of cardiac function. THC treatment also attenuated 
fibrosis within myocardium in THC-received diabetic mice by up-regulation of SIRT1 signaling 
pathway expression. THC treatment was also accompanied by suppression of acetylation and 
stimulation of deacetylation of SOD2, a SIRT1 downstream molecule reinforcing the anti-
oxidative capacity. The administration of THC inhibited TGFβ1/Smad3 signaling pathway 
This is a post-peer-review, pre-copyedit version of an article published in Heart Failure Reviews. The 
final authenticated version is available online at: https://doi.org/10.1007/s10741-019-09854-6. 
15 
 
activated by reactive oxygen species (ROS). The collagen deposition was significantly reduced 
after THC exposure in the cardiac tissue of diabetic mice [49]. 
Conclusion 
Mounting evidence, both in vitro and in vivo, support the anti-fibrotic functions of Cur and its 
analogues in the presence of various pro-fibrotic factors (Table 1). Cur reverses the effect of pro-
fibrotic factors through altering the expression and activation of numerous intracellular molecules.  
These evidences suggest that curcumin and its metabolites could potentially act as an effective 
adjuvant to inhibit the progression of myocardial damage resulting from various conditions that 
may lead to heart failure. It can be implied that Cur is a safe herbal medication that merely targets 
the cells responsible for the disease, while leaving normal ones unaffected. Various measures 
including the use of altered formulations of Cur, concomitant administration of Cur with agents 
reducing its metabolism and designing oral delivery systems using structures such as liposomes 
and nanoparticles are necessary to tackle the low bioavailability of Cur. 
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Figure 1. Epigenetic mechanisms in the formation of pro-fibrotic myofibroblasts. Following an 
injury or a stress, resident cardiac fibroblasts activate and differentiate into myofibroblasts. 
Myofibroblasts secrete extracellular matrix components (ECM), such as collagen, laminin, and 
fibronectin, and form fibrotic tissue. Epigenetics is a key player in this pro-fibrotic response, 
therefore it can be addressed for therapeutic purposes. Histone deacetylase (HDAC) inhibitors 
(mocetinostat, trichostatin A and MPT0E014 a pan HDAC inhibitor) have a direct action both on 
transforming growth factor beta (TGF-β) and cytokines including interleukin 6 (IL-6). Resveratrol 
activates Sirtuin 3 (SIRT-3) that indirectly blocks TGF-b/Smad3 pathway, thus suppressing 
fibroblast-to-myofibroblast transformation. Demethylating agents, such as 5-azacytidine can 
silence Ras association domain family 1 isoform A (RASSF1A), a tumor suppressor gene involved 
in fibroblast activation, and prevent cardiac fibrosis. Several cardiac microRNAs (miRNAs) have 
a cardio-protective activity by targeting the expression of TGF-β and pro-fibrotic cytokines (miR-
133, miR30, miR15, and miR-378). Anti-miR-208 acts on the TGF-β/Smad3 pathway. Anti-miR-
21 and anti-miR-19b can regulate TGF-β1-mediated endothelial-to-mesenchymal transition via 
PTEN/Akt pathway. In endothelial cell, down-regulation of SET1 by HDAC inhibitors attenuates 
Ang II-induced cardiac fibrosis. Moreover, bone morphogenetic protein 7 (BMP7), an anti-fibrotic 
morphogen agent can reactivate Ras protein activator like 1 (RASAL1), thus reducing Ras-GTP 
activity and endothelial to mesenchymal transition (EndMT). With permission from [1] 
 
Figure 2. Cur decreased collagen deposition in the left ventricles of SHRs.  WKY rats were used 
as controls, and SHRs were treated with saline, Cur (100 mg·kg-1·d-1), or Cur (100 mg·kg-1·d-
1)+GW9662 (10 mg·kg-1·d-1) by oral gavage for 12 weeks.  Sirius Red staining was used to 
analyze the levels of collagen deposition in the left ventricles of WKY or SHRs (n=8 rats, each 
group).  Scale bar: 100 μm.  WKY: Wistar Kyoto rats; SHRs: spontaneously hypertensive rats. 
With permission from [13] 
